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Mikhail A Panteleev1,2,3* and Hendrik Coenraad Hemker4Laboratory testing in hemostasis is a subject of growing
concern among the specialists. To put it plainly, the
standard assays that have been in widespread use for
more than 40 years (APTT and PT assays for clotting,
aggregometry for platelets) are not sensitive and specific
for too many major disorders of hemostasis; their parame-
ters can remain within normal ranges when patient is in
acute danger of thrombosis or bleeding; even if they do
detect some abnormality they do not indicate the severity
of the clinical manifestations; in rare cases they are even
abnormal in a clinically asymptomatic individual.
Admittedly, as already recognized by Virchow in his
famous Virchow’s triad, thrombosis can arise from disor-
ders in either vessel wall, blood flow, or blood compos-
ition and laboratory diagnostics only concerns the latter.
If the origin of a thrombotic or bleeding disorder is not
in the blood, as in myocardial infarction caused by ath-
erosclerotic plaque rupture, there is no need for the
blood to be in a hyper-coagulable state before the event
and laboratory diagnostics of coagulation or platelet
function can be completely normal (although some
non-hemostatic biomarkers for e.g. atherosclerotic plaque
instability do exist [1]).
The same holds for hemostasis: the extent of bleeding
is determined by the state of the tissue (type and degree
of damage, tissue composition at the injury site), phys-
ical parameters of the wound and blood flow (geometry
of the wound, blood flow patterns there) as well as blood
biochemistry. No functional assay of blood clotting is
likely to be able to predict hemorragic stroke resulting
from aneurism rupture or bleeding in a person with
hereditary hemorrhagic telangiectasia or Ehlers–Danlos
syndrome, exactly because there is originally nothing
wrong with their blood in these cases.* Correspondence: mapanteleev@yandex.ru
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article, unless otherwise stated.Nevertheless, even in a perfectly normal population
the function of the clotting system does determine the
likelihood and degree of hemostasis and thrombosis. It
is for instance well documented that normal persons
with blood group O bleed more and have a smaller risk of
thrombosis than those with non-O blood groups [2-5].
This is directly related to their having less factor VIII and
Von Willebrand factor and higher anti-thrombin activity.
Recognizing that the “coagulability” of the blood tells
only part of the story cannot justify to acquiesce to the
inefficiency of the traditional clotting- and platelet
assays. There are too many cases where their results
are not correct, even when the origin of the hemostatic
abnormality is clearly systemic and is to be found in the
blood. A typical example is the hypercoaguable state
that results from the presence of circulating coagulation
activators in blood (microparticles activating clotting via
tissue factor [6] or contact pathway [7], long-lived clotting
enzymes like factors IXa, XIa, and XIIa [7-9]). One of
the leading Russian hematologists, Andrey Vorobyov,
recommended spontaneous clotting of blood in the syr-
inge needle observed during blood collection as one of
the typical indicators of the hypercoagulative stage of
disseminated intravascular coagulation, usually coinciding
with normal APTT [10], and cited this as a regrettable ex-
ample of why a doctor can hardly rely on the available
traditional laboratory diagnostics tools in coagulation.
Less striking examples include the lack of correlation
between prolongation of APTT and clinical manifestations
in all hemophilias and factor XII deficiency; the insensi-
tivity of clotting assays to thrombophilias like factor V
Leiden; the insensitivity of platelet aggregometry to
many platelet disorders like Scott syndrome and gray plate-
let syndrome and its inapplicability in thrombocytopenia,
etc. Then there is the problem of the control of anti-
coagulant therapy. A profound international effort has
succeeded to establish the INR as a reliable way to control
anti-vitamin K prophylaxis. For heparins, however, the
APTT is worthless but for the detection of over-dosage
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only hides our incapacity to establish their effect in a
patient with any degree of accuracy. This is the more
serious as there are large individual differences in the
response to the same dose of heparin [11].
A particulary severe problem is monitoring of the novel
pro-coagulant and anti-thrombotic agents: traditional
clotting methods (for coagulation) or aggregometry (for
platelets) either do not detect effects of recombinant
activated factor VII, anti-TFPI agents, new direct anti-
coagulants, P2Y12 antagonists or do this without clear
relation to clinical efficiency.
Why is it so? Is there a way to resolve this inefficiency
of traditional assays?
A reasonable explanation is that these assays do not
meet the criteria of an adequate physiological function
test: if circulating microparticles, or factor XIIa, or the
factor VLeiden mutation increase thrombotic risk but do
not affect APTT then there is something wrong with the
APTT design. The two possible solutions are obvious: a)
to develop adequate physiological function tests that re-
flect all complexities of in vivo clotting or (inclusive or!)
b) to complement them by molecular diagnostic tools
able to sense the individual (risk) factors.
The second approach, despite being less decisive and
somewhat ambiguous, has become state of the art in the
last decennia, is intuitively simpler and is being thor-
oughly explored and widely used. At the present mo-
ment, a doctor has in its arsenal a wide range of
methods to determine levels of individual clotting factor
precursors, inhibitors, active circulating factors, micro-
particles of various origin, pro-thrombotic mutations,
anti-Xa activity, fibrinolysis activity, expression of vari-
ous proteins on the platelet membrane, platelet granule
contents, and many others. This ‘coagulogram’ is import-
ant, because in many cases it allows determination of
the specific mechanisms behind the thrombotic or
bleeding disorder. Still, this approach has major limi-
tations: a) the large and extremely expensive series of
possible tests is far from being complete and cannot be-
come comprehensive, the blood coagulation network
and platelets being as complex as it is; b) knowledge
about the individual components does not allow to
estimate the over-all function, will not give a conclusive
estimate of the overall hemostatic/thrombotic risk. Throm-
botic or bleeding risk results from a combination of
changes in several of the components of the hemostatic
system [12]. As in the case of the O and non-O blood
groups, all individual factors may be in the normal
range and yet the hemostatic/thrombotic tendency is
significantly influenced. In liver cirrhosis the lack of
prothrombin is compensated for by a lack of antithrombin,
that itself is partly compensated by a rise in α2-
macroglobulin (Kremers RMW, Kleinegris M-C, CateHT, Wagenvoord RJ, Hemker HC: Decreased prothrombin
conversion and thrombin inactivation result in rebalanced
thrombin generation in liver cirrhosis. In preparation).
Sometimes platelets can even compensate for the defects of
plasma coagulation [13].
There should be a way to evaluate the overall inter-
action for diagnostic reasons (is the problem to be
sought in the blood?), for screening of hemostatic risks
(e.g. preoperatively), for screening of thrombotic risk (is
prophylaxis indicated?) and for measuring the effects of
prophylactic- and therapeutic measures. In short, there
should be global-, integral assays of hemostasis [14,15].
It is hard to give a precise definition of “global assay”.
It could be said that they are function tests of the
hemostatic system, where assay conditions are chosen so
that the measured parameters reflect the interaction of
all components of the hemostatic system in the same
way as they do in vivo; thus allowing adequate evalu-
ation of their contribution and interaction with each
other. Indeed, global assays are experimental in vitro
models of hemostasis/thrombosis that aim to mimic all
important aspects of the physiological (and patho-
logical) system both as to biochemistry and biophysics.
Complete “physiological adequacy” is the holy grail of
the ultimate function testing but also partly solutions
are already welcome.
Complete physiological adequacy may be asking too
much. None of the existing global assays actually in-
volves all components of hemostasis. The thrombin gen-
eration (TG) assay, one of the leading and established
methods of this class, focuses on blood coagulation,
though it can detect platelet functions via their effect on
blood coagulation [16]. Within blood coagulation, use of
thrombin generation assay for diagnostics of defects in
fibrinogen, fibrinolysis, protein C system usually requires
some modifications of the assay [17]. Thromboelasto-
graphy, another major global approach, is sensitive for
defects in platelet aggregation and fibrinolysis, but not
platelet adhesion. Clot waveform analysis is actually an
advanced version of APTT, with critically important
advantages but with many of its limitations remaining in
place. Thrombodynamics explicitly includes spatial het-
erogeneity of blood coagulation, spatial propagation and
diffusion of clotting enzymes, but not platelet aggrega-
tion or adhesion [7]. Various perfusion flow systems for
observation of thrombus formation in vitro aim to add
platelet adhesion to the list, sometimes in combination
with coagulation (two such systems currently available
commercially are PFA and T-TAS [18]), but introduction
of all this complexity raises completely new questions
and issues.
The purpose of the paper collection “Global assays of
hemostasis” published by the Thrombosis Journal that we
present here is to summarize state-of-the-art knowledge
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advantages and drawbacks, the possibilities to use them in
everyday practice and problems to overcome [19-22].
Two papers in our collection deal with the description
of the existing assays and those under development.
The one by Lance focuses on the three established
major assays: thrombin generation, thrombelastography
and clot waveform analysis [20]. Another, by Tynngard
et al., picks up the storyline to make a transition to de-
scription and critical analysis of new global assays ranging
from free oscillation rheometry and thrombodynamics to
flow perfusion chambers and PFA-100 [22].
Two other papers focus on the representative critical
problems in the field. The contribution of Brinkman
deals with the important aspect of working with novel
oral anticoagulants [19]. One advantage of the global
assays is that they (if physiologically adequate) can be
used for the detection and monitoring of novel drugs
that have no adequate effect on traditional assays (novel
anticoagulants, bypassing agents, etc.). Indeed the rise of
innovative oral anticoagulants is a major challenge for
laboratory diagnostics these days, and one where global
assays can be invaluable. Finally, the article by Lipets
and Ataullakhanov investigates the above-described
problem of hypercoagulation, insensitivity to which is
also the major drawback of the traditional assays [21].
Their analysis aims to summarize the existing experience
of employing global assays for the prediction of throm-
botic risks of various origins.
Some of the issues remained outside the scope of the
above discussion. One prominent problem is preanaly-
tics: the high sensitivity of global assays makes them
particularly vulnerable to inaccuracies and variables of
sample collection and preparation [23,24]. It is said that
Armand Quick calibrated his stopwatches on the length
of the “prothrombin time” being twelve seconds. The
robustness of the test alas reflects its insensitivity and
the inverse is – regretfully – true as well, hence the
problem of overall standardization of the assays [25].
A third problem is their mathematical modeling, its
potential usefulness [26] and issues [27] (although pres-
ently the thrombin generation assay is the only well-
established global assay, for which kinetic models do
exist and that date from long before the present upsurge
of the assay [28]). Finally, there remain many specific
clinical problems apart from those described above and
use of global assays for each of them deserves a separate
discussion. A traditional special issue, like the present
one cannot be expected to give a complete survey of all
open problems.
Despite the promise and numerous successes the glo-
bal assays still remain a diverse group of methods. In
fact, when blood or plasma clots, there is hardly a phys-
ical parameter that does not change: turbidity, electricalconductance, viscocity, mechanical resistance, probably
also NMR and so on and so forth. Each of them can be
transformed into a global essay. The normal range of its
parameters can be determined. Then we can establish
the correlation between abnormal parameters and path-
ology and this may serve diagnostic purposes – may be
called a global test A good function test, however, shows
correlation because there is a direct relation between the
outcome of the test and the (patho-) physiological func-
tion. Heart failure may be estimated from the degree of
shortness of breath, nocturia, edema, venous pressure
and a number of other signs and symptoms. Left ven-
tricular function is at the basis of these phenomena and
therefore that is the essential variable. In the same manner
it appears to us that the generation of thrombin is the
essential contribution of the plasma to hemostasis, a
phenomenon that more directly than clotting times and
other derived phenomena reflects an essential function.
The last word in these matters is to medical useful-
ness. Global methods are an advanced tool that still has
a long way to go before becoming universally accepted
in clinical practice.
It is our hope that the present volume can serve to
make these assays more familiar to the hemostasis spe-
cialists and may contribute to their further development
and spreading.Competing interests
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